Notably this study included only wild‐type EGFR cell lines and did not specifically evaluate EGFR mutant patients, so further studies are needed to elucidate the interactions between DRD1 and EGFR and investigate the potential utility of targeting DRD1 in EGFR mutant NSCLC patients. The gene discussed is DRD1; the disease is non-small cell lung carcinoma.